Clinical trial · Observational
Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
Background: Cancer pain can have a very negative effect on people s daily lives. Researchers want to use machine learning to detect facial expressions and voice signals. They want to help people with cancer by creating a model to measure pain. They want the model to reflect diverse faces and facial expressions. Objective: To find out whether facial recognition technology can be used to classify pain in a diverse set of people with cancer. Also, to find out whether voice recognition technology can be used to assess pain. Eligibility: People ages 12 and older who are undergoing treatment for cancer Design: Participants will be screened with: Cancer history Information about their sex and skin type Information about their access to a smart phone and wireless internet Questions about their cancer pain Participants will have check-ins at the clinic and at home. These will occur over about 3 months. They will have 2-4 check-ins at the clinic. They will check in at home about 3 times per week. During check-ins, participants will answer questions and talk about their cancer pain. They will use a mobile phone or a computer with a camera and microphone to complete a questionnaire. They will record a video of themselves reading a 15-second passage of text and responding to a question. During the clinic check-ins, professional lighting, video equipment, and cameras will be used for the recordings. During remote check-ins, participants will be asked to complete the questionnaire and recordings alone. They should be in a quiet and bright room. The room should have a white wall or background.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (16)
- label
- 1DF/NoPain_IV-VI_Female
- description
- Worst pain in past month = 0; Skin Type IV-VI, Female
- label
- 1DM/NoPain_IV-VI_Male
- description
- Worst pain in past month = 0; Skin Type IV-VI, Male
- label
- 1LF/NoPain_I-III_Female
- description
- Worst pain in past month = 0; Skin Type I-III, Female
- label
- 1LM/NoPain_I-III_Male
- description
- Worst pain in past month = 0; Skin Type I-III, Male
- label
- 2DF/MildPain_IV-VI_Female
- description
- Worst pain in past month = 1-3; Skin Type IV-VI, Female
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 120 Years
Show eligibility criteria text
* INCLUSION CRITERIA: 1. Ability of subject to understand and willingness to sign a written informed consent document. 2. Adults and children (including NIH staff) aged \>= 12 years. 3. Participants with diagnosis of a cancer or tumor 4. Participant must be receiving either standard of care or investigational cancer/tumor treatment either at NIH or with a community physician. 5. Must have access to a smart phone (iPhone or Android) with either a data plan and/or access to wireless internet (wifi) or a computer with a camera and microphone and access to internet and must willing to use their device and assume any associated charges from service providers. EXCLUSION CRITERIA: 1. Participants with progressive brain tumors or metastasis. Participants with treated brain metastasis or primary brain tumor are eligible if there is no evidence of progression for at least 4 weeks after CNS directed treatment and there is no impact on voice or facial muscle movements. 2. Participants with Parkinson s disease. 3. Known current alcohol or drug abuse. 4. Any psychiatric condition that would prohibit the understanding or rendering of informed consent. 5. Non-English speaking subjects.
References
Publications (0)
Data not yet available